黄热病疫苗接种数据的真实世界证据驱动研究
本研究利用TriNetX平台电子健康记录,识别2017至2021年美国接种Stamaril®黄热病疫苗的15,835人,将真实世界证据获得的不良事件发生率与制造商近期研究报告比较。结果与已发表数据一致,所有年龄组接种后不良医学结局未见显著增加,尤其在长期分析中;该概念验证研究支持真实世界证据用于疫苗安全性监测。
要点
- 基于TriNetX电子健康记录识别2017至2021年美国接种Stamaril®黄热病疫苗者共15,835人。
- 真实世界证据所得不良事件发生率与制造商近期研究报告一致。
- 所有年龄组接种后不良医学结局未见显著增加,长期分析尤其如此。
核心结论
- 真实世界证据所得结果与既往发表数据一致,提示所有年龄组接种后不良医学结局未见显著增加,尤其在长期分析中。
研究设计与样本
- 概念验证研究,分析TriNetX平台电子健康记录,识别2017至2021年美国接种Stamaril®黄热病疫苗的15,835人,并与制造商近期研究报告的不良事件率进行比较。
主要发现
- 真实世界证据获得的不良事件率与制造商近期关于该期间美国使用Stamaril®的研究报告一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Yellow Fever (YF), a mosquito-borne viral disease caused by yellow fever virus (YFV), remains endemic in tropical Sub-Saharan Africa and South America. The 17D live-attenuated vaccine has significantly reduced YF incidence with minimal risk of vaccine-associated adverse events, including Yellow Fever Vaccine-fever-associated Neurotropic Disease (YEL-AND) and Yellow Fever Vaccine-Associated Viscerotropic Disease (YEL-AVD). This study investigates the potential of Real-World Evidence (RWE) to enhance vaccine surveillance by analyzing electronic health records (EHRs) from the TriNetX platform, which identified a total of 15,835 individuals who were vaccinated with the Stamaril® YF vaccine between 2017 and 2021 in the United States. We compared adverse event rates obtained from RWE with those reported by the manufacturer in a recent study of Stamaril® used in the United States during this period. Our findings were consistent with those published previously and suggest no significant increase in adverse medical outcomes post-vaccination across all age groups, particularly in long-term analysis. This proof-of-concept study underscores the value of RWE in monitoring vaccine safety and supports its potential to complement traditional surveillance methods, offering a robust tool for continuous post-marketing vaccine evaluation.
引用
- Farnsworth MG, Khanipov K, Botnar K, et al. Real-world evidence of yellow Fever vaccination data-driven study. Vaccine. 2025. PMID: 39848130. doi:10.1016/j.vaccine.2025.126758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。